Bank of Montreal Can Decreases Stock Holdings in Novavax, Inc. (NASDAQ:NVAX)

Bank of Montreal Can cut its stake in shares of Novavax, Inc. (NASDAQ:NVAX - Free Report) by 99.4% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 14,315 shares of the biopharmaceutical company's stock after selling 2,440,010 shares during the period. Bank of Montreal Can's holdings in Novavax were worth $115,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of NVAX. Spire Wealth Management bought a new position in shares of Novavax in the fourth quarter worth about $29,000. New Age Alpha Advisors LLC purchased a new stake in Novavax during the 4th quarter valued at approximately $35,000. KBC Group NV raised its position in shares of Novavax by 97.0% during the fourth quarter. KBC Group NV now owns 7,954 shares of the biopharmaceutical company's stock valued at $64,000 after buying an additional 3,917 shares during the last quarter. TigerOak Management L.L.C. purchased a new position in shares of Novavax in the fourth quarter worth $86,000. Finally, AlphaQuest LLC grew its stake in Novavax by 290.1% during the fourth quarter. AlphaQuest LLC now owns 10,677 shares of the biopharmaceutical company's stock valued at $86,000 after acquiring an additional 7,940 shares in the last quarter. 53.04% of the stock is owned by hedge funds and other institutional investors.

Novavax Stock Up 3.0 %

NVAX traded up $0.19 on Wednesday, reaching $6.61. 3,777,099 shares of the company traded hands, compared to its average volume of 8,345,896. The company has a market cap of $1.06 billion, a P/E ratio of -2.92, a price-to-earnings-growth ratio of 2.85 and a beta of 3.15. The firm has a fifty day simple moving average of $7.07 and a two-hundred day simple moving average of $8.27. Novavax, Inc. has a one year low of $4.25 and a one year high of $23.86.

Novavax (NASDAQ:NVAX - Get Free Report) last released its quarterly earnings data on Thursday, February 27th. The biopharmaceutical company reported ($0.51) EPS for the quarter, topping the consensus estimate of ($0.75) by $0.24. The firm had revenue of $88.31 million for the quarter, compared to analysts' expectations of $85.48 million. During the same quarter in the previous year, the business earned ($1.44) earnings per share. On average, equities analysts forecast that Novavax, Inc. will post -1.46 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on NVAX shares. TD Cowen raised Novavax to a "hold" rating in a report on Thursday, February 27th. BTIG Research initiated coverage on shares of Novavax in a report on Friday, February 28th. They issued a "buy" rating and a $19.00 price target for the company. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the company. According to MarketBeat, Novavax presently has a consensus rating of "Hold" and a consensus price target of $18.00.

About Novavax

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.